Company Overview

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

Read More Corporate Presentation Corporate Fact Sheet

Latest News

Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting

May 15, 2024

IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

May 13, 2024

IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024

Financial Events

Imunon’s First Quarter 2024 Financial Results

May 13, 2024 at 11:00 AM EDT

Imunon’s Fourth Quarter 2023 Financial Results

March 28, 2024 at 10:00 AM EDT